The Europe cancer vaccines market size is estimated to expand at a significant CAGR of 9.8% during the forecast period, 2021–2028. The growth of the market is attributed to the rising number of cancer cases, as well as scientific advancements in cancer vaccinations, along with massive cancer-care costs.
Cancer vaccines are considered vaccines that are designed to improve the body's natural immune response to cancer to avoid or treat cancer. Biological response regulators are drugs including cancer vaccinations. These biological response modifiers help the body's immune system to combat cancer by boosting it. Cancer vaccines are divided into two categories: therapeutic cancer vaccines and preventive cancer vaccines. Preventive cancer vaccinations are given to normal people to help them avert cancer. Cancer patients are given therapeutic cancer vaccines to boost their immune system's ability combat the disease. Cancer vaccinations can be given intravenously to both adults and children.
Furthermore, owing to a large number of cancer cases and the negative impacts of current medications, healthcare professionals are seeking alternative remedies.
Market Trends, Drivers, Restraints, and Opportunities
- Smoking, liquor, and poor eating habits are key risk factors for rising cancer cases, are projected to spur the market growth during the forecast period.
- Increasing medication research in the field of cancer, government assistance, growing elderly population, growing medical services and investments, increasing awareness of cancer rates, and existing treatments are major factors pushing the market expansion in the coming years.
- High cost of cancer vaccines and the extended period needed to make a single vaccine are estimated to hinder the market growth.
- Shortages of cancer vaccines in remote areas, as well as the need for cold handling and distribution, possess as main challenges that can restrict the market expansion in the coming years.
- Removal of regulations and the resumption of R&D projects and clinical studies for cancer vaccines are expected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the Europe cancer vaccines market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Cancer Vaccines Market - Europe Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Technologies (Viral Vector and DNA Cancer Vaccines, Whole-cell Cancer Vaccines, Recombinant Cancer Vaccines, and Others), Treatment Methods (Therapeutic Vaccines and Preventive Vaccines), and Applications (Cervical Cancer, Prostate Cancer, and Others)
|
Geographies
|
United Kingdom, Germany, France, Spain, Italy, and the Rest of Europe
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Amgen Inc.; Sanofi SA; Aduro Biotech, Inc.; Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC); Bristol-Myers Squibb; GlaxoSmithKline PLC; Merck & Co. Inc.; and OSE Immunotherapeutics
|
Europe Cancer Vaccines Market Segment Insights
Recombinant cancer vaccines segment is projected to constitute a major market share
Based on technologies, the Europe cancer vaccines market is divided into viral vector and DNA cancer vaccines, whole-cell cancer vaccines, recombinant cancer vaccines, and others. The recombinant cancer vaccines segment is expected to hold a key share of the market during the forecast period owing to the increasing use of recombinant technology, increased use of recombinant vaccines, and a rise in the number of licensed cancer vaccines produced utilizing recombinant technology are all driving the segment's growth.
Preventive vaccines segment is expected to grow at a robust pace
On the basis of treatment methods, the market is segmented into therapeutic vaccines and preventive vaccines. The preventive vaccines segment is expected to account for a key share of the market in the coming years due to vaccinations aimed at preventing cancer in healthy persons are known as preventive or prophylactic vaccines. These vaccinations function by protecting against infectious pathogens that can potentially contribute to cancer. Gardasil 9, Gardasil, and Cervarix vaccinations have been licensed by the European Medical Authority to prevent people from cervical cancer as well as other HPV-related malignancies and pre-cancerous disorders.
Cervical cancer segment is anticipated to expand at a rapid CAGR
In terms of applications, the Europe cancer vaccines market is segregated into cervical cancer, prostate cancer, and others. The cervical cancer segment is expected to constitute a key share of the market during the forecast period owing to the higher incidence of cervical cancer and the rising number of individuals infected with the human papillomavirus (HPV). Furthermore, the segment's expansion is fueled by a growth in the elderly people, therapeutic innovation in the field of cervical cancer, and increased patient knowledge of the disease.
Spain is anticipated to dominate the market
On the basis of geographies, the market is categorized as United Kingdom, Germany, France, Spain, Italy, and the Rest of Europe. Spain is anticipated to expand at a healthy CAGR during the forecast period. The market growth can be attributed to the patient awareness of cancer treatment is increasing, as is the use of cancer vaccines in combination with other medicines and the rise in cancer patients.
Segments
Segments Covered in the Report
The Europe cancer vaccines market has been segmented based on
Technologies
- Viral Vector and DNA Cancer Vaccines
- Whole-cell Cancer Vaccines
- Recombinant Cancer Vaccines
- Others
Treatment Methods
- Therapeutic Vaccines
- Preventive Vaccines
Applications
- Cervical Cancer
- Prostate Cancer
- Others
Geographies
- United Kingdom
- Germany
- France
- Spain
- Italy
- the Rest of Europe
Key Players
- Amgen Inc.
- Sanofi SA
- Aduro Biotech, Inc.
- Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC)
- Bristol-Myers Squibb
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- OSE Immunotherapeutics
Competitive Landscape
Key players competing in the Europe cancer vaccines market include Amgen Inc.; Sanofi SA; Aduro Biotech, Inc.; Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC); Bristol-Myers Squibb; GlaxoSmithKline PLC; Merck & Co. Inc.; and OSE Immunotherapeutics. Some of these players are adopting several business strategies such as acquisitions, mergers, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares.
